-
When a Short Fuse Becomes a Storm: Understanding Irritability in Huntington’s Disease
Latest News
-
Inside the Brain’s Theme Park: How Huntington’s Disease Disrupts the Emotion Coaster
Welcome to Brainland, the bustling, 24/7 theme park in your head. There’s Memory Maze, Logic Log Flume, and of course, the Emotion Coaster, where your brain races through tracks themed around happiness, sadness, and anger. However, for some people who carry the gene for Huntington’s disease (HD), some of these rides start acting up long…
-
What’s Good for Your Heart is Good for Your Brain: New Study Links Cardiovascular Health to Brain Aging
Heart health has been linked to lower levels of NfL, a key biomarker of brain cell damage in Huntington’s disease. This suggests heart-healthy habits – like exercise and diet – may have an effect on protecting the brain & keeping NfL in check.
-
Assembly Line Breakdown: Protein Production Problems in Huntington’s Disease
Huntington’s disease slows the cell’s protein factory, causing production line jams & toxicity. A faulty blueprint & missing factory assistant worsen errors. Targeting production slowdowns, not just misfolded products, may help fix the assembly line.
-
April 2025: This Month in Huntington’s Disease Research
HDBuzz has ramped up to match the accelerating pace of Huntington’s disease research. April 2025 brought us insight on somatic expansion, replacing lost brain cells, and clinical trial updates. Read on for the highlight reel from this month!
-
Stopping C-A-G Repeat Expansion In Its Tracks
A new study shows that lowering MSH3, a key DNA repair protein, with antisense oligonucleotide (ASO) therapy can stop CAG repeat expansions in HD patient-derived brain cells. This could be a promising way to slow symptom onset and progression.
-
Ten Golden Rules for Navigating Huntington’s Disease Research News
Avoid the hype: HDBuzz has Ten Golden Rules for navigating news stories or press releases about Huntington's disease.
-
Roche provides an update on tominersen: What’s next for this huntingtin-lowering drug?
Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is continuing, but only the higher dose will move forward. What does this update mean for the HD community and this trial?
-
Knockouts for the win: how expanding CAGs drive disease
A recent paper links CAG repeat expansion with widespread RNA changes, especially in brain cells vulnerable to HD. “Knocking out” certain DNA repair genes that go awry in HD can have positive effects on features of HD in mice.
-
Piecing It Back Together: Growing new neurons for Huntington’s disease
New research suggests the adult brain can be convinced to grow new neurons to replace those lost in Huntington’s disease. The SUPER exciting part? These cells don’t just grow—they seem to connect and function, like puzzle pieces clicking into place.
-
Stars in the Sky: Psychosis in Huntington’s Disease
New research shines a light on an often-overlooked side of Huntington’s disease—psychosis. Understanding the impact of psychosis on daily life and progression of other HD symptoms could be key to providing better care and support.
-
Do Antidepressants Affect Cognitive Decline? There's More To The Story For Huntington's Disease
Recent research suggests a connection between antidepressant use and increased cognitive decline in people with dementia. However these finding shouldn't be blindly applied to Huntington's disease.